William C. Reinhold

SCLC TumorMiner is a genomics platform that provides molecular classification, biomarker identification, and drug-response analysis for small cell lung cancer using integrated datasets from multiple institutions.

This paper identifies SEMA7A as a prognostic biomarker in adrenocortical carcinoma using transcriptome data from TCGA and NCI samples, showing its association with poor prognosis and specific signaling pathways.

The paper identifies RPL22 as a splicing regulator linking rRNA synthesis to mRNA splicing, showing that Pol I inhibition reverses RPL22-dependent alternative splicing.

The paper identifies MPC1 as a key driver of PARP inhibitor resistance in NSCLC lung cancer through a metabolism-focused CRISPR screen.

This study identifies a 24-protein panel distinguishing TNBC from other breast cancers and shows proteomics improves drug sensitivity predictions.

This study rapidly generates proteomic data for NCI-60 cancer cell lines and identifies drug response determinants by integrating proteomic, genetic, and transcriptomic data.

CellMinerCDB integrates pharmacogenomic data from multiple cancer cell line databases to identify drug response determinants, reproducibility, and novel genomic signatures.